CD133

VALUE_ERROR (nil)
Identifiers
Aliases
External IDs	GeneCards: [1]
Orthologs
Species	Human	Mouse
Entrez	n/a	n/a
Ensembl	n/a	n/a
UniProt	n/a	n/a
RefSeq (mRNA)	n/a	n/a
RefSeq (protein)	n/a	n/a
Location (UCSC)	n/a	n/a
PubMed search	n/a	n/a
Wikidata
View/Edit Human

CD133 antigen also known as prominin-1 is a glycoprotein that in humans is encoded by the PROM1 gene. It is a member of pentaspan transmembrane glycoproteins (5-transmembrane, 5-TM), which specifically localize to cellular protrusions. While the precise function of CD133 remains unknown, it has been proposed to act as an organizer of cell membrane topology.

Tissue distribution

CD133 is expressed in hematopoietic stem cells, endothelial progenitor cells, glioblastoma, neuronal and glial stem cells, various pediatric brain tumors, as well as adult kidney, mammary glands, trachea, salivary glands, placenta, digestive tract, testes, and some other cell types.

Clinical significance

A CD133⁺ cell population in brain tumors is thought to be a cancer stem cell (CSC) population, which is rare, undergoes self-renewal and differentiation, and can propagate tumors when injected into immune-compromised mice. However, subsequent studies have indicated the difficulty in isolating pure CSC populations. CD133⁺ melanoma cells are considered a subpopulation of CSC a critical role in recurrence. Moreover, CD133⁺ melanoma cells are immunogenic and can be used as an antimelanoma vaccination. In mice the vaccination with CD133⁺ melanoma cells mediated strong anti-tumor activity that resulted in the eradication of parental melanoma cells. In addition, it has also been shown that CD133⁺ melanoma cells preferentially express the RNA helicase DDX3X . As DDX3X also is an immunogenic protein, the same anti-melanoma vaccination strategy can be employed to give therapeutic antitumor immunity in mice.

See also

• Stargardt disease

Further reading

• Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y (2009). "CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas". Pancreas. 38 (8): e207–14. doi:10.1097/MPA.0b013e3181bb5037. PMID 19786935.
• Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G (2009). "Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment". Proc. Natl. Acad. Sci. U.S.A. 106 (38): 16281–6. doi:10.1073/pnas.0905653106. PMC 2741477. PMID 19805294.
• Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I (2010). "CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients". Int. J. Cancer. 126 (4): 950–8. doi:10.1002/ijc.24822. PMID 19676044.
• Nishide K, Nakatani Y, Kiyonari H, Kondo T (2009). Lowenstein PR, ed. "Glioblastoma Formation from Cell Population Depleted of Prominin1-Expressing Cells". PLoS ONE. 4 (8): e6869. doi:10.1371/journal.pone.0006869. PMC 2729925. PMID 19718438.
• Na YR, Seok SH, Kim DJ, Han JH, Kim TH, Jung H, Lee BH, Park JH (2009). "Isolation and characterization of spheroid cells from human malignant melanoma cell line WM-266-4". Tumour Biol. 30 (5–6): 300–9. doi:10.1159/000261073. PMID 19940551.
• Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S, Smith A (2009). Chédotal A, ed. "CD133 (Prominin) Negative Human Neural Stem Cells Are Clonogenic and Tripotent". PLoS ONE. 4 (5): e5498. doi:10.1371/journal.pone.0005498. PMC 2676510. PMID 19430532.
• Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK (2009). "Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large Scale Evaluation of Genetic Variants". Cancer Prev Res (Phila Pa). 2 (7): 617–24. doi:10.1158/1940-6207.CAPR-09-0025. PMC 2964280. PMID 19584075.
• Yao J, Zhang T, Ren J, Yu M, Wu G (2009). "Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells". Oncol. Rep. 22 (4): 781–7. doi:10.3892/or_00000500. PMID 19724856.
• Yasuda H, Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Kawamoto A, Inoue Y, Miki C, Kusunoki M (2009). "Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer". Oncol. Rep. 22 (4): 709–17. doi:10.3892/or_00000491. PMID 19724847.
• Yoshikawa S, Zen Y, Fujii T, Sato Y, Ohta T, Aoyagi Y, Nakanuma Y (2009). "Characterization of CD133+ parenchymal cells in the liver: Histology and culture". World J. Gastroenterol. 15 (39): 4896–906. doi:10.3748/wjg.15.4896. PMC 2764966. PMID 19842219.
• Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G (2009). "CD133 antigen expression in ovarian cancer". BMC Cancer. 9: 221. doi:10.1186/1471-2407-9-221. PMID 19583859.
• Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J (2009). "Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer". Histopathology. 55 (3): 284–93. doi:10.1111/j.1365-2559.2009.03378.x. PMID 19723143.
• Friedman S, Lu M, Schultz A, Thomas D, Lin RY (2009). Breant B, ed. "CD133+ Anaplastic Thyroid Cancer Cells Initiate Tumors in Immunodeficient Mice and Are Regulated by Thyrotropin". PLoS ONE. 4 (4): e5395. doi:10.1371/journal.pone.0005395. PMC 2671400. PMID 19404394.
• Cheng JX, Liu BL, Zhang X (2009). "How powerful is CD133 as a cancer stem cell marker in brain tumors?". Cancer Treat. Rev. 35 (5): 403–8. doi:10.1016/j.ctrv.2009.03.002. PMID 19369008.
• Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2009). "Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer". Cancer Invest. 27 (8): 844–50. doi:10.1080/07357900902744502. PMID 19626493.
• Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC (2009). "CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection". BMC Cancer. 9: 324. doi:10.1186/1471-2407-9-324. PMC 2753636. PMID 19744348.
• Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, Zhang X, Pan ZZ, Wan DS, Zeng YX, Zhu XF, Zhang XS (2009). "Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB". J Transl Med. 7: 56. doi:10.1186/1479-5876-7-56. PMC 2715381. PMID 19583834.
• Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y (2009). "CD133 gene overexpression is frequently observed in early colorectal carcinoma". Hepatogastroenterology. 56 (93): 995–7. PMID 19760928.
• Pras E, Abu A, Rotenstreich Y, Avni I, Reish O, Morad Y, Reznik-Wolf H, Pras E (2009). "Cone-rod dystrophy and a frameshift mutation in the PROM1 gene". Mol. Vis. 15: 1709–16. PMC 2732717. PMID 19718270.
• Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G (2009). "Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors". Clin. Cancer Res. 15 (13): 4299–311. doi:10.1158/1078-0432.CCR-08-1883. PMID 19509143.

External links

• GeneReviews/NCBI/NIH/UW entry on Retinitis Pigmentosa Overview
• Human PROM1 genome location and PROM1 gene details page in the UCSC Genome Browser.